Neoadjuvant chemotherapy for locally advanced oral mucosal cancer

Introduction. Oral mucosal cancer is one of the most complex tumors of the head and neck. most patients seek help with a locally advanced process where the tumor affects surrounding organs and tissues. Surgical treatment in such cases is accompanied by significant functional and aesthetic disorders, and 5-year disease-free survival does not exceed 50 %. In this regard, additional treatments for oral mucosal cancer, such as neoadjuvant chemotherapy, which can improve survival rates, are being actively investigated.

Aim. To evaluate the efficacy of neoadjuvant chemotherapy and its impact on survival in patients with locally advanced oral mucosal cancer.

Materials and methods. The study included 188 patients with resectable locally advanced stage III–Iv oral mucosal cancer (T2 – T4N0–2c) who were treated at the N. N. Blokhin National Oncology Research medical Center from 2013 to 2023. patients were divided into 2 groups. group 1 (n = 38) included patients who underwent neoadjuvant chemotherapy followed by surgery, group 2 (n = 150) included patients who underwent surgical treatment with adjuvant radiation / chemoradiation therapy. In 55.3 % of cases, the DCf regimen (docetaxel, cisplatin, 5-fluorouracil) was used, in 18.4 % – Cp (carboplatin, paclitaxel), in 26.3 % – pf (cisplatin, 5-fluorouracil). Clinical and morphological responses were assessed by solid tumor response criteria (Response evaluation criteria in solid tumors, RECIST 1.1). Statistical analysis was performed using IBm SpSS Statistics 27 software.

Results. In 44.7 % of patients with locally advanced oral mucosal cancer, neoadjuvant chemotherapy provides a clinical response to treatment, in 25 % of patients – with a pronounced morphological tumor response (grade III–Iv). It was found that in the neoadjuvant chemotherapy group, the incidence of disease progression is significantly lower than in the surgical treatment group (34.2 % versus 53.3 %), overall survival rates are better (48.7 % versus 40.4 %). In patients with a pronounced morphological response after neoadjuvant chemotherapy, the recurrence rate was lower than in patients with a worse response: in 12.5 and 29.2 % of cases, respectively. Nevertheless, there were no significant differences in survival rates between the neoadjuvant and surgical treatment groups (p = 0.063).

Conclusion. Neoadjuvant chemotherapy contributes to improved treatment outcomes for locally advanced oral mucosal cancer. An increase in the number of patients with a pronounced morphological response can lead to a statistically significant increase in survival rates.

1. Parkin D.M., Bray F., Ferlay J. et al. Global cancer statistics. 2002. CA Cancer J Clin 2005;55(2):74–108. DOI: 10.3322/canjclin.55.2.74

2. Hanna G.J., Haddad R.I., Lorch J.H. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist 2012;18(3):288–93. DOI: 10.1634/theoncologist.2012-0286

3. Licitra L., Grandi C., Guzzo M. et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003;21(2):327–33. DOI: 10.1200/JCO.2003.06.146

4. Zhong L.P., Zhang C.P., Ren G.X. et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 2013;31(6):744–51. DOI: 10.1200/JCO.2012.43.8820

5. Inhestern J., Schmalenberg H., Dietz A. et al. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell carcinoma (TISOC – 1). Ann Oncol 2017;28(8):1917–22. DOI: 10.1093/annonc/mdx202

6. Huang Y., Sun J., Li J. et al. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate trial). Int J Surg 2023:109(8):2220–7. DOI: 10.1097/JS9.0000000000000489

7. Chaukar D., Prabash K., Rane P. et al. Prospective phase II openlabel randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. J Clin Oncol 2022;40(3):272–81. DOI: 10.1200/JCO.21.00179

8. Patil V.M., Noronha V., Muddu V.K. et al. Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference? Indian J Cancer 2013;50(1):1–7. DOI: 10.4103/0019-509X.112263

9. Wutong J., Yiyi Z., Ying L. et al. Can adjuvant radiotherapy be omitted for oral cavity cancer patients who received neoadjuvant therapy and surgery? A retrospective cohort study. Int J Surg 2023;109(4):879–86. DOI: 10.1097/JS9.0000000000000353